Aspirin is known to lower risk for some cancers, and a new UCSF-led study points to a possible explanation, with the discovery that aspirin slows the accumulation of DNA mutations in abnormal cells in at least one pre-cancerous condition.
June 18, 2013
June 18, 2013
Lisa Kroon, PharmD, has been named the new chair of the Department of Clinical Pharmacy within the UCSF School of Pharmacy, effective July 1. Kroon has served as interim chair of the department since July 2012, when the previous chair, B. Joseph Guglielmo, PharmD, became interim dean and later dean of the School of Pharmacy.
May 09, 2013
Two UCSF scientists — brain researcher Michael Brainard, PhD, and cell biologist Dyche Mullins, PhD — have been selected to be Howard Hughes Medical Institute investigators.
April 29, 2013
Some of the most widely prescribed antidepressant medications are associated with increased risk of bleeding, transfusion, hospital readmission and death when taken around the time of surgery, according to an analysis co-led by UCSF.
March 22, 2013
The Li Ka Shing Foundation has pledged $2 million to support UCSF’s efforts to advance precision medicine, an emerging field aimed at revolutionizing medical research and patient care.
March 21, 2013
UCSF has named a highly accomplished pharmacist and clinical scientist, B. Joseph Guglielmo, PharmD, a 34-year member of the UCSF faculty, to lead the nation’s premier School of Pharmacy.
December 17, 2012
Drugs and medical devices tend to appear more beneficial in scientific papers if they were manufactured by the company that sponsored the study, showing that who pays for the clinical trial has a direct impact on the reported outcome, according to a new analysis by researchers at UCSF and the Cochrane Collaboration.
December 06, 2012
The rate of cancer survival is expected to keep climbing in coming years largely thanks to research discoveries that are translating into new cancer drugs, which currently account for roughly 30 percent of the pharmaceutical dollar, the chief scientific officer at Bristol-Myers Squib recently said at a showcase event for the UCSF Helen Diller Family Comprehensive Cancer Center.
November 06, 2012
Hospitalized heart failure patients who received the drug, serelaxin, in a phase III clinical trial had fewer disease symptoms and as a group experienced 37 percent fewer deaths over six months, according to results of a new study.
September 04, 2012
Pharmaceutical companies now have a guide — the UCSF-FDA TransPortal — to pre-clinical studies they should conduct to identify potentially harmful interactions between existing and new drugs that depend on how the drugs move into and out of cells through protein portals known as transporters.